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Abstract
Introduction Anti-oestrogens have been the mainstay of therapy
in patients with oestrogen-receptor (ER) positive breast cancer
and have provided significant improvements in survival.
However, their benefits are limited by tumour recurrence in a
significant proportion of initially drug-responsive breast cancer
patients because of acquired anti-oestrogen resistance.
Relapse on such therapies clinically presents as local and/or
regional recurrences, frequently with distant metastases, and
the prognosis for these patients is poor. The selective ER
modulator, tamoxifen, classically exerts gene inhibitory effects
during the drug-responsive phase in ER-positive breast cancer
cells. Paradoxically, this drug is also able to induce the
expression of genes, which in the appropriate cell context may
contribute to an adverse cell phenotype. Here we have
investigated the effects of tamoxifen and fulvestrant treatment
on invasive signalling and compared this with the direct effects
of oestrogen withdrawal to mimic the action of aromatase
inhibitors.
Methods The effect of oestrogen and 4-hydroxy-tamoxifen on
the invasive capacity of endocrine-sensitive MCF-7 cells, in the
presence or absence of functional E-cadherin, was determined
by Matrigel invasion assays. Studies also monitored the impact
of oestrogen withdrawal or treatment with fulvestrant on cell
invasion. Western blotting using phospho-specific antibodies
was performed to ascertain changes in invasive signalling in
response to the two anti-oestrogens versus both oestradiol
treatment and withdrawal.
Results To the best of our knowledge, we report for the first
time that tamoxifen can promote an invasive phenotype in ER-
positive breast cancer cells under conditions of poor cell-cell
contact and suggest a role for Src kinase and associated pro-
invasive genes in this process. Our studies revealed that
although this adverse effect is also apparent for further classes
of anti-oestrogens, exemplified by the steroidal agent fulvestrant,
it is absent during oestrogen withdrawal.
Conclusions These data highlight a previously unreported
effect of tamoxifen (and potentially further anti-oestrogens), that
such agents appear able to induce breast cancer cell invasion in
a specific context (absence of good cell-cell contacts), where
these findings may have major clinical implications for those
patients with tumours that have inherently poor intercellular
adhesion. In such patients oestrogen deprivation with
aromatase inhibitors may be more appropriate.
Introduction
Despite the undoubted benefits that endocrine therapies have
brought for breast cancer patients in terms of increased sur-
vival, de novo and acquired resistance to such treatments
presents a major clinical problem; not all patients with oestro-
gen-receptor (ER) positive disease benefit and a significant
number of initially-responsive patients ultimately relapse on
such treatments [1]. The selective ER modulator tamoxifen has
been the mainstay of therapy for almost two decades, and
much has been learned about acquired resistance to this anti-
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oestrogen. To date, mechanistic studies have revealed impor-
tant roles for growth factor signalling pathways such as those
regulated by the epidermal growth factor receptor (EGFR) and
human epidermal growth factor receptor (HER) 2, as contrib-
utors to endocrine resistance [2]. Significantly, in addition to
antagonising oestrogen (E2)-regulated gene expression,
tamoxifen can promote the re-expression of E2-repressed
genes and, importantly, regulate the expression of a unique
subset of E2-independent genes [3].
The consequences of such events are only now becoming
clear, with recent data suggesting that the ability of selective
ER modulators, such as tamoxifen, and the steroidal anti-oes-
trogen, fulvestrant, to induce expression of signal transduction
genes normally repressed by oestrogen/ER signalling may
play an important role in the ability of breast cancer cells to
evade their growth inhibitory effects [4,5]. Moreover, such
treatments may modulate the expression of genes associated
with an adverse cell behaviour; for example, in ER-positive
breast cancer cells, tamoxifen has been reported to increase
expression of 14-3-3, a marker of poor prognosis in breast
cancer patients [6].
In addition to their genomic effects, selective ER modulators
may also exert non-genomic effects on target cells; for exam-
ple, tamoxifen has been demonstrated to induce activation of
mitogen-activated protein kinase (MAPK) [7], focal adhesion
kinase (FAK) [8] and Src [8,9], signalling elements frequently
linked to tumour migration and invasion [10,11]. Interestingly,
Src kinase is also implicated in limiting the response of
tamoxifen, where it stimulates the weak AF-1 function of the
tamoxifen-ER complex through its tyrosine kinase activity [12].
Furthermore, in 3Y1 rat fibroblasts, which overexpress Src
kinase, tamoxifen cooperates with Src to cause cellular trans-
formation through induction of DNA synthesis and anchorage-
independent cell proliferation [13].
E-cadherin is an intercellular adhesion protein important for
maintenance of cell-cell adhesion and tissue integrity [14] and
much evidence links alterations in its expression with the
advent of invasive growth in epithelial tumours [15]. The func-
tional disruption of E-cadherin using monoclonal antibodies
can promote Src-dependent cellular invasion [16] and con-
versely, Src activation has been demonstrated to be essential
to the progression of early diffuse gastric tumours, where it is
associated with a loss of E-cadherin and the development of
local invasion [17]. Significantly, in breast cancer cells, the
presence of a functional ER has been shown to be necessary
for expression of E-cadherin [18], thus suggesting that its
expression and subsequent cell-cell adhesion, may be modu-
lated by anti-oestrogens and may have a bearing on the inva-
sive growth of tumours.
In the current report, we propose a further mechanism that
may provide a route for progression of breast cancer in the
face of ER inhibition with anti-oestrogens. We have studied
the effects of tamoxifen on MCF-7 cells deficient in E-cad-
herin-mediated homophilic interactions and demonstrate that
in a cellular context of reduced intercellular adhesion,
tamoxifen promotes an invasive cell phenotype through a proc-
ess involving the activation of Src kinase. Although also noted
with the steroidal anti-oestrogen fulvestrant, this effect of inva-
sion in tamoxifen treated cells was not seen under conditions
of oestrogen withdrawal. This evidence suggests that, in vivo,
a loss of E-cadherin may predict a poor patient outcome on
tamoxifen therapy, and may account for some of the additional
benefits seen with aromatase inhibitors.
Materials and methods
Cell culture
Tamoxifen-responsive, wild-type MCF-7 cells (wtMCF-7) were
routinely cultured in RPMI medium (Invitrogen, Paisley, UK)
supplemented with 5% foetal calf serum (FCS), antibiotics (10
IU/ml penicillin and 10 g/ml streptomycin), 2.5 g/ml fungi-
zone, 200 mM glutamine and incubated at 37°C in a 5% car-
bon dioxide atmosphere. For experimental analysis, the
medium was changed to experimental medium, which is oes-
trogen depleted, (phenol-red-free RPMI containing 5% char-
coal-stripped, steroid-depleted FCS, glutamine and antibiotics
as above) for 24 hours before undertaking the relevant assays
as described below. These experimental conditions were
maintained for oestrogen withdrawal studies, although for anti-
oestrogen and hormone treatments the culture medium was
supplemented with 10-7 M 4-hydroxy-tamoxifen ('tam'), 10-9 M
oestrogen ('E2') or 10-7  M fulvestrant ('Faslodex', Astra-
Zeneca, UK). All tissue culture media and constituents were
obtained from Life Technologies Europe Ltd (Paisley, UK) and
tissue culture plasticware was obtained from Nunc (Rosklide,
Denmark).
Antibodies and reagents
The antibodies used were as follows: anti-phospho Src kinase
(Y418) from Cell Signalling Technologies (New England
Biolabs, Herts, UK); pan-Src antibody from Biosource (Invitro-
gen, Paisley, UK); glyceraldehyde 3-phosphate dehydroge-
nase (GAPDH) antibody from ABCAM (Cambridge UK); an
anti-E-cadherin antibody with neutralising activity (HECD-1)
was purchased from R & D Systems Ltd. (Oxford, UK). For
immunofluorescence microscopy, the anti-E-cadherin anti-
body, SHE-78, (Invitrogen, UK) was used.
siRNA-mediated suppression of E-cadherin in MCF-7 
cells
E-cadherin protein expression was suppressed by siRNA
transfection of MCF-7 cells as follows: SMARTpool siRNA
against human E-cadherin gene (CDH-1) was obtained from
Dharmacon Ltd (Perbio Science UK Ltd., Northumberland,
UK) and used according to the manufacturer's instructions.
Briefly, MCF-7 cells were seeded into six-well plates at 5 ×
105 cells/well in antibiotic-free medium with or without anti-Available online http://breast-cancer-research.com/content/10/6/R103
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hormone where appropriate. After 24 hours culture, the
medium was replaced with fresh, antibiotic-free medium or
medium containing transfection lipid, 100 nM non-targeting
siRNA control or 100 nM SMARTpool siRNA specific for
CDH1 (E-cadherin). Cells were assayed for E-cadherin protein
expression after 24, 48 and 72 hours post-transfection by
Western blotting to confirm protein knockdown. For invasion
assays and Western blotting analysis, cells were treated with
CDH1 siRNA for 72 hours before performing the experiments
in the presence or absence of the agents as detailed.
Basement membrane invasion assay
Cell invasion was determined using invasion chambers pos-
sessing 8 m porous membranes (BD Biosciences, Oxford,
UK) coated with Matrigel (0.4 g/ml). Cells (treated as above)
were seeded into the chambers (105 cells/well) with or without
anti-hormone and 600 l of medium was added to the outside
of the well. Inserts were cultured at 37°C in a tissue culture
incubator for 48 hours, after which the non-invasive cells and
Matrigel were removed from the inside of the wells with a cot-
ton swab. After fixing the invaded cells with 3.7% formalde-
hyde, the porous membranes were removed form the invasion
chamber using a scalpel blade and mounted onto a glass
microscope slide using Vectashield (Molecular Probes,
Eugene, OR, US) containing the nuclear stain 4',6-diamidino-
2-phenylindole. Cell invasion was quantified by viewing five
separate fields per membrane at a magnification of × 20 and
counting the number of cells in each field. Data were then plot-
ted at mean cells per field ± SD for a minimum of three inde-
pendent experiments, each performed in triplicate.
Cell lysis and Western blotting
After cell cultures were treated as described above, the cells
were washed twice with ice-cold PBS and lysed in lysis buffer
(50 mM Tris, pH 7.5, 5 mM ethylene glycol tetraacetic acid,
150 mM sodium chloride and 1% Triton X100) containing pro-
tease inhibitors (2 mM sodium orthovanadate, 20 mM sodium
fluoride, 1 mM phenyl-methylsulfonyl fluoride, 20 M pheny-
larsine, 10 mM sodium molybdate, 10 g/ml leupeptin and 8
g/ml aprotinin). The lysates were placed on ice for 20 min-
utes with intermittent mixing and clarified by centrifugation (10
minutes, 13,000 rpm, 4°C).
The concentration of solubilised proteins was then determined
using the DC protein assay kit (BioRad, Hemel Hempstead,
UK). From these lysates, 50 g of total protein was separated
by SDS-PAGE using 8% gels and transferred to nitrocellulose
membranes by electroblotting. Membranes were subse-
quently blocked with 5% (w/v) milk protein in Tris-buffered
saline containing 0.05% Tween-20. Blots were then incu-
bated with primary antibodies as indicated, washed in Tris-
buffered saline containing 0.05% Tween-20 and incubated
with horseradish peroxidase-conjugated secondary antibod-
ies. An enhanced chemiluminescence system ('West Dura'
reagent, Pierce and Warriner Ltd, Chester, UK) was used for
subsequent detection of bound antibodies and the blots
exposed to X-ray film (Kodak, UK). Blots shown are represent-
ative of a minimum of three separate experiments. Each blot
was scanned using a densitometer in order to obtain data for
statistical analysis.
Immunofluorescent staining
Cells were cultured on eight-well chamber slides and allowed
to reach log phase growth before being treated with CDH1
siRNA ± tamoxifen as above for a further period of 72 hours.
Cells were then fixed with 3.7% formaldehyde, permeablised
using 0.05% TritonX-100 and blocked with 10% normal goat
serum for 30 minutes. Staining for E-cadherin was carried out
using 1 g/ml SHE78 antibody for 60 minutes followed by
anti-mouse immunoglobulin (Ig) G:fluorescein isothiocyanate
conjugate (Molecular Probes, Ugene, Oregon, USA) at
1:2000 for 30 minutes. Co-staining for actin was performed by
incubating the cells with phalloidin (Invitrogen, Carlsbad, Cal-
ifornia, USA), in PBS containing 1% BSA. Cells were then
washed and mounted onto microscope slides using a hard-set
mounting medium (Vectashield, Molecular Probes, Invitrogen,
Carlsbad, California, USA). Cells were viewed at a magnifica-
tion of × 63 with an oil-immersion objective and representative
cells photographed.
Immunocytochemical staining
Log-phase cells, grown on glass cover slips in experimental
medium, were left untreated (control) or treated with tamoxifen
(10-7 M) or oestrogen (10-9 M) for four days. Cells were fixed
in 2% paraformaldehyde/vanadate for 20 minutes before
being washed three times for five minutes with PBS. After
blocking with PBS-Tween (0.02% v/v), cells were incubated in
primary antibody overnight followed by a peroxidise-labelled
secondary antibody (DAKO enVision system (DAKO UK Ltd,
Ely, Cambridge, UK) for one hour. After washing, bound anti-
bodies were detected using DAB substrate with counterstain-
ing using 0.02% methyl green solution. Stained cells were
rinsed, air dried and mounted onto glass slides using a xylene
soluble mounting medium.
Cell growth assay
Cells were seeded into 24-well plates before treating with
CDH1 siRNA in the presence or absence of tamoxifen and a
range of inhibitors, as described, for 72 hours. After this time,
wells were gently washed and cells fixed with formaldehyde
(3.7% in PBS). The numbers of cells in each well were then
determined using a coulter counter. Data was obtained as cell
counts (mean of three separate wells) for each treatment, with
experiments performed in duplicate.
Statistical analysis
Statistical significance was determined with paired student's
t-test of the data using MiniTab14. Significance was observed
at p  0.05.Breast Cancer Research    Vol 10 No 6    Borley et al.
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Results
Tamoxifen, but not E2-withdrawal, promotes invasion of 
MCF-7 cells in the absence of intercellular contacts
The capacity of ER-positive, MCF-7 breast cancer cells to
invade through Matrigel in response to tamoxifen or oestrogen
withdrawal (-E2) was determined and compared with E2
alone. MCF-7 cells are poorly invasive in vitro [19] and their
invasive capacity was not significantly affected by -E2, while
tamoxifen alone had only a minor effect. Interestingly, a non-
significant trend emerged, with tamoxifen treatment resulting
in increased cell invasion compared with -E2, which in turn
caused more invasion than in cells exposed to E2 (Figure 1a).
Whereas neutralising E-cadherin function using the HECD-1
antibody promoted a modest increase in cell invasion, invasion
in response to combined treatment (tamoxifen + the antibody)
was significantly higher (figure 1b). The use of this antibody in
combination with either E2 or under E2-withdrawal conditions
('-E2'), however, did not promote a increase in invasion (Figure
1b). These changes were not due to changes in cell prolifera-
tion, because cell proliferation rates were unchanged over the
short timescale of the experiment (data not shown).
To further confirm that tamoxifen could induce cellular invasion
in the absence of intercellular adhesion, we transfected MCF-
7 cells with siRNA for the CDH1 (E-cadherin) gene. Cells
treated in this way displayed a significant loss of E-cadherin
protein, an effect maintained over a period of 72 hours (Figure
2a, b) in contrast to cells treated with either the siRNA delivery
lipid or a non-targeting siRNA ('L' and 'NT' respectively). Inter-
estingly, these data appeared to show that tamoxifen
increased E-cadherin expression compared with -E2. How-
ever, a caveat to this was that these samples were run on sep-
arate gels. Thus, to confirm the effects of endocrine
manipulation on E-cadherin expression, immunoblots were
performed using samples treated with -E2, +E2 or tamoxifen.
These data showed that none of the treatments tested had a
significant effect on E-cadherin expression (Figure 2c).
siRNA effects were further confirmed with immunofluores-
cence analysis of E-cadherin expression. Whereas strong
staining for E-cadherin could be detected in untreated MCF7
cells (Figure 2d, left two panels), very little or no E-cadherin
was observed following 48 hours siRNA treatment (right pan-
els). By co-staining for actin (bottom row), changes in cellular
morphology were observed following siRNA-mediated CDH1
suppression. Interestingly, in the samples which were treated
with siRNA and tamoxifen combined, the numbers of cells with
a more spherical appearance appeared to increase, an event
previously linked to enhanced cellular migration [20] (Figure
2d).
As was the case with the antibody, siRNA-mediated suppres-
sion of E-cadherin in the absence of oestrogen resulted in an
increase in the numbers of cells invading through the Matrigel
basement membrane, although the extent of this was variable
(Figure 3a) and overall not significant. However, when
tamoxifen was included in this system, the numbers of invading
cells was considerably higher (Figure 2a). No effects on inva-
sion were observed following treatment of the cells with either
transfection lipid or the non-targeting siRNA, or the addition of
E2 (data not shown). Whilst cell growth assays confirmed that
these cells were responsive to E2 and antihormones irrespec-
tive of E-cadherin expression (Figure 3b), the increases in inva-
sion following antihormone treatment were again not
attributable to changes in cellular proliferation as there were
no significant changes in cell growth as a consequence of any
treatment over the short experimental time period (6 days)
(Figure 3c). To determine whether these effects were non-
specific and independent of the ER, ER-negative MDA-MB-
231 cells were treated similarly. However, no increase in inva-
sion of these cells was seen (Figure 3d).
Tamoxifen-induced invasion in E-cadherin deficient 
MCF7 cells involves increases in Src kinase activity
Tamoxifen can activate Src kinase [8] known to promote the
invasive phenotype of tamoxifen-resistant MCF-7 cells [21].
Thus, in an attempt to elucidate the mechanism by which
tamoxifen may promote invasive behaviour in the absence of
intercellular adhesion, we investigated the expression and
Figure 1
Tamoxifen induces invasion in HECD-1-treated breast cancer cells Tamoxifen induces invasion in HECD-1-treated breast cancer cells. 
The invasive capacity of MCF-7 cells having (a) functional or (b) anti-
body (HECD-1)-inhibited E-cadherin was determined in the presence 
of E2 (10-9 M), oestrogen-free (-E2) or tamoxifen-treated conditions 
(10-7 M). E2 did not significantly alter the invasive ability of MCF-7 cells 
in either case, whereas (b) tamoxifen treatment of HECD-1-treated 
cells promoted a dramatic increase in invasive capacity. Graphs are 
representative of three independent experiments with error bars indicat-
ing the standard deviation. *p < 0.05 versus treatment with HECD-1 
antibody alone.Available online http://breast-cancer-research.com/content/10/6/R103
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activity of Src kinase. Src phosphorylation at Y418 was
increased in all cells treated with tamoxifen compared with -
E2, and was significantly higher in cells treated with the com-
bination of CDH1 siRNA and tamoxifen (Figure 4a, b).
To determine the functional relevance of elevated Src activity,
invasion assays were performed following siRNA and
tamoxifen treatment and in the presence of the Src kinase
inhibitor, SU6656. Treatment of cells with SU6656 (2.5 M)
inhibited Src kinase activity in all treatment samples while hav-
ing no effect on total Src levels (Figure 5a). The invasive
capacity of these cells was then determined in the presence
or absence of SU6656, alongside inhibitors of the EGFR (1
M gefitinib) and HER2 (100 nM traztuzumab), both previ-
ously reported to be upregulated following prolonged
tamoxifen treatment in MCF-7 cells [5,22,23]. In these experi-
ments, only inhibition of Src kinase activity was able to signifi-
cantly suppress the invasion of tamoxifen-treated, E-cadherin-
deficient MCF-7 cells (Figure 5b). This was not due to inhibi-
tion of cellular growth, as none of the inhibitors tested signifi-
cantly altered cellular growth over a period of 72 hours, the
time period over which the invasion assays were carried out
(Figure 5c).
Figure 2
Modulation of E-cadherin expression in MCF-7 cell using siRNA Modulation of E-cadherin expression in MCF-7 cell using siRNA. (a) MCF-7 cells were left untreated (control, 'C') or treated with transfection 
lipid ('L'), non-targeting (scrambled) siRNA ('NT') or E-cadherin-specific siRNA ('CDH1') for the times indicated in the presence or absence of 
tamoxifen. Cells were then lysed and the lysates probed for E-cadherin. (b) Densitometry analysis was performed on three separate sample sets and 
plotted as mean percentage change ± standard deviations *p < 0.05 versus control. siRNA treatment significantly inhibited E-cadherin expression 
over a period of 72 hours irrespective of the presence of tamoxifen. (c) To determine whether E2 or tamoxifen-modulated E-cadherin expression, 
cells were treated with E2 or tamoxifen, lysed and probed for E-cadherin and -actin. Neither E2 nor tamoxifen significantly altered E-cadherin 
expression in these cells. (d) MCF-7 cells were treated with plain medium (oestrogen free) or CDH1 siRNA for 72 hours in the presence or absence 
of tamoxifen before immunofluorescence staining of E-cadherin (green) and actin (red). Cells were then visualised by fluorescence microscopy and 
representative pictures taken of the same field of view using fluorescein isothiocyanate (FITC) and TRITC (Tetramethyl rhodamine isothiocyanate) fil-
ters. Very little or no E-cadherin was detectable after siRNA treatment. Inclusion of tamoxifen alongside the siRNA appeared to increase the numbers 
of cells having a spherical morphology.Breast Cancer Research    Vol 10 No 6    Borley et al.
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The steroidal anti-oestrogen fulvestrant also enhances 
breast cancer cell invasion in the absence of E-cadherin 
expression
To determine whether the invasion-promoting effects of
tamoxifen could also be achieved with a different class of anti-
oestrogen, experiments were repeated using the steroidal
agent fulvestrant instead of tamoxifen. Our data revealed that
fulvestrant is also able to induce cellular invasion in the
absence of E-cadherin (Figure 6a), whereas oestrogen with-
drawal did not. Moreover, in the absence of E-cadherin, only
fulvestrant treatment was accompanied by an apparent
increase in Src kinase activity (Figure 6b). As was the case for
tamoxifen, no gain in invasion was seen after fulvestrant treat-
ment of the ER-negative, E-cadherin-negative MDA-MB-231
cells (Figure 6d).
Discussion
Adjuvant endocrine therapy has been a major contributor to
the decline in breast cancer mortality in the Western world,
with the effectiveness of tamoxifen in women with ER-positive
cancers clearly demonstrated in many trials [24]. More
recently, the dominance of tamoxifen has been challenged by
the advent of the aromatase inhibitors, anastrazole, letrozole
and exemestane. A number of large randomised trials (e.g.
BIG98, MA17 and ATAC [25-27]) have examined the efficacy
of aromatase inhibitors in the adjuvant therapy of ER-positive
postmenopausal patients, assessing upfront therapy versus
tamoxifen, sequential therapy and extended therapy beyond
five years. The encouraging results of these studies have led
to aromatase inhibitors becoming a standard component of
care for these patients. There is also continuing interest in ster-
oidal anti-oestrogens, such as fulvestrant in breast cancer,
currently being explored through trials at various stages of the
clinical management of the breast cancer patient. However,
Figure 3
Tamoxifen promotes invasion of E-cadherin deficient MCF-7 cells Tamoxifen promotes invasion of E-cadherin deficient MCF-7 cells. (a) MCF-7 cells were left untreated (control, 'C') or treated with transfection 
lipid ('L'), non-targeting (scrambled) siRNA ('NT') or E-cadherin-specific siRNA ('CDH1') for 72 hours before assessing their invasive capacity in oes-
trogen-free and tamoxifen-containing medium. siRNA-mediated suppression of E-cadherin expression alone promoted an increase in cell invasion 
through Matrigel. Inclusion of tamoxifen in CDH1-treated cells resulted in a further increase in invasive capacity. The graph is the mean of three sep-
arate experiments. *p < 0.01 versus CDH siRNA treatment. (b) MCF-7 proliferation was determined in response to E2 ± tamoxifen and fulvestrant in 
the presence and absence of E-cadherin. Data demonstrated that these cells were responsive to both E2 and anti-oestrogens irrespective of E-cad-
herin presence. *p < 0.05 versus E2 alone. (c) The growth of untreated MCF7 cells or cells treated with lipid (L), non-targeting siRNA (NT) or CDH-
1 siRNA (CDH1) over five days was determined by coulter counting. No treatment significantly affected cellular growth over this time period. (d) 
MDA-MB-231 cells were treated with siRNA ± tamoxifen and changes in their invasion determined. Tamoxifen did not have any significant effect on 
MDA-MB-231 cell invasion.Available online http://breast-cancer-research.com/content/10/6/R103
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despite these advances, the optimal endocrine therapy for an
individual patient remains uncertain. In addition, a significant
number of patients will still experience a recurrence during
endocrine therapy and ultimately die of their disease.
It is becoming apparent that administering endocrine agents
such as tamoxifen has effects far beyond their initially
described mechanism of action and thus attempting to under-
stand the failure of such therapy is a complex problem. Emerg-
ing evidence suggests that tamoxifen can modulate cellular
processes linked to migratory and invasive responses in vitro.
For example, tamoxifen can induce FAK-mediated cytoskeletal
remodelling [9] and the expression of matrix metalloprotein-
ases [28] by non-genomic mechanisms. Additionally, since the
majority of changes in gene expression after oestrogen stimu-
lation are largely thought to be of a repressive nature [3], anti-
hormones themselves may promote the re-expression of such
genes. Although many of these oestrogen-repressed genes
may be growth inhibitory, and thereby contribute to tamoxifen-
induced suppression of cell growth, it is increasingly recog-
nised that anti-hormones also induce many genes with an
ontology that is not easily reconciled with growth inhibition.
Indeed, expression of such genes may contribute towards lim-
iting maximal anti-tumour activity of these agents in ER-positive
breast cancer cells [29,30] as is suggested by the ability of
tamoxifen and further anti-oestrogens to promote early induc-
tion of EGFR and HER2 [5], genes linked to tamoxifen resist-
ance and an adverse cell phenotype.
Furthermore, in the light of reports demonstrating that oestro-
gens confer a protective effect on invasiveness and motility
[31] one might expect anti-hormones to reverse this process.
However, despite data from ourselves and others demonstrat-
ing a significant, tamoxifen-dependent induction of pro-inva-
sive genes in anti-hormone responsive cells, this does not
subsequently translate out into a significant increase in cellular
invasive capacity in vitro, although a previous study by Mathew
and colleagues [32] demonstrated increased healing of MCF-
7 cell wounds in vitro in response to tamoxifen. Intriguingly,
however, our data here indicate the full impact of anti-oestro-
gen-induced genes may only be manifested under conditions
of poor cell-cell contact. Thus, siRNA-induced depletion of E-
cadherin-mediated intercellular adhesion, while promoting a
modest increase in cellular invasion, greatly enhances the abil-
ity of tamoxifen to induce invasive behaviour in MCF-7 cells.
Clearly, while this anti-oestrogen confers only small increases
Figure 4
Tamoxifen induces Src-kinase activity in E-cadherin-deficient MCF-7 cells Tamoxifen induces Src-kinase activity in E-cadherin-deficient MCF-7 cells. (a) MCF-7 cells were treated with plain medium ('C'), transfection 
lipid ('L'), non-targeting siRNA ('NT') or CDH1 siRNA ('CDH1') for 72 hours before culture in oestrogen-free or tamoxifen-containing medium. Cells 
were lysed then immunoprobed for activated Src (Src phosphorylated at Y418), total Src (pan Src) and Glyceraldehyde-3-Phosphate Dhydroge-
nase (GAPDH). (b) Replicate immunoprobings were scanned and the data normalised to semi-quantitate the effects of tamoxifen or oestrogen with-
drawal on Src activity in the absence of E-cadherin. siRNA-mediated inhibition of E-cadherin combined with tamoxifen caused an increase in the 
levels of phosphorylated Src detectable in these cells. *p < 0.05 versus untreated cells.Breast Cancer Research    Vol 10 No 6    Borley et al.
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in invasiveness under conditions of good cell-cell contact, this
may become substantial where cell-cell contact is compro-
mised. These observations are interesting clinically, given that
studies have shown that up to 40% of non-lobular breast can-
cers show reduced or absent E-cadherin expression [33],
associated with a poorer prognosis [34,35]. To date, however,
it is unknown as to whether E-cadherin status correlates with
survival on, or response to, tamoxifen treatment.
Our data suggests that underlying these phenomena is an
increase in the activity of Src kinase. Although it has been pre-
viously shown that inhibition of E-cadherin function can lead to
elevated Src activity [16], our study indicated only a small,
non-significant increase in Src phosphorylation following
knockdown of the E-cadherin gene. These apparent discrep-
ancies may arise from the fact that in our study, Src activity
was monitored after long-term (72 hours) knockdown of E-
cadherin expression, compared with short-term (30 minutes),
antibody-mediated E-cadherin disruption in the previous case.
The effect of tamoxifen on Src activity in this system is interest-
ing in light of the role of Src in cellular invasion. Elevated Src
activity is reported in a variety of solid tumours, including
breast cancer, and its expression has been shown to increase
with disease progression, suggesting an important role in inva-
sion and metastasis [36]. In vitro studies have also shown that
elevated Src kinase promotes an aggressive and invasive phe-
notype in tamoxifen-resistant cells [10] and has been linked to
the induction of epithelial-to-mesenchymal transition [37,38].
The relevance of Src activity to tamoxifen-induced cellular
invasion in our model is further demonstrated by the fact that
inhibition of Src phosphorylation significantly reduced
tamoxifen-induced invasion in the absence of E-cadherin. The
observation that Src inhibition did not completely reverse
tamoxifen-induced invasion suggests there are other important
mechanisms involved.
Interestingly, the adverse inductive effects do not appear to be
specific to the selective ER modulator tamoxifen, because our
studies reported here showed that similar invasive responses,
and a corresponding increase in Src activity, could also be
observed after treatment with fulvestrant (a steroidal anti-oes-
trogen). Critically, we observed that such events were absent
under conditions of oestrogen withdrawal and were not seen
in an ER-negative, E-cadherin negative cell line (MDA-MB-
231). In total, these data indicate the induction of aggressive
cellular behaviour in this model system is a unique conse-
quence of anti-oestrogen occupancy of the oestrogen
receptor.
Figure 5
Inhibition of Src kinase prevents tamoxifen-induced cellular invasion in E-cadherin deficient MCF-7 cells Inhibition of Src kinase prevents tamoxifen-induced cellular invasion in E-cadherin deficient MCF-7 cells. (a) MCF-7 cells were treated with 
CDH1 siRNA and tamoxifen in the presence or absence of the Src kinase inhibitor, SU6656 (2.5 M). SU6656 inhibited Src kinase activity in each 
of the samples examined. (b) MCF-7 cell invasion was determined in E-cadherin deficient MCF-7 cells in the presence of tamoxifen alone, or 
tamoxifen plus the epidermal growth factor receptor (EGFR) inhibitor, gefitinib ('TKI'), the Src inhibitor, SU6656 ('SU') or the human epidermal 
growth factor receptor 2 (HER2) inhibitor, herceptin ('Her'). Inhibition of Src activity prevented the tamoxifen-induced invasion in E-cadherin-deficient 
cells. *p < 0.05 versus cells treated with siRNA and tamoxifen. (c) Cell growth in the presence of the same inhibitors was determined by counting 
the numbers of cells present in the wells of a 24-well plate after 72 hours treatment as shown. No treatment significantly affected cellular growth 
over this time period.Available online http://breast-cancer-research.com/content/10/6/R103
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The mechanism by which anti-oestrogens, such as tamoxifen,
promote increased Src activity in the absence of E-cadherin is
currently unclear. Tamoxifen, itself, can activate signalling
pathways via growth factor receptors [39]. Conversely, E-cad-
herin expression suppresses the activity of receptor tyrosine
kinases upstream of Src, such as the EGFR [40]. It is evi-
denced by the positive regulation of E-cadherin in in vivo sys-
tems such as the Apc+ mouse facilitating negative regulation
of EGFR and associated signalling molecules including Src
[41]. Moreover, mice bearing germline mutations in Apc, dis-
play impaired E-cadherin-mediated adhesion together with
augmented EGFR and Src activity [42]. Thus, the loss of E-
cadherin may allow the subsequent activation of growth factor
receptors by tamoxifen acting to augment Src kinase activity
and leading to an enhanced invasive phenotype. To this end
we have investigated the expression and activity of EGFR fam-
ily members in MCF-7 cells under conditions of E-cadherin
deficiency and tamoxifen but have not observed any alteration
in expression or activity (A. Borley, unpublished data). How-
ever, this does not rule out the role of other growth factor
receptors in this process and current studies are underway to
address this issue and identify potential candidates.
Our data show that tamoxifen and fulvestrant significantly
induce invasion in MCF-7 cells where the E-cadherin intercel-
lular-mediated intercellular adhesion is disrupted, and that
activation of Src kinase plays an important role in this process.
The clinical implications of these findings are that patients with
breast cancers exhibiting aberrant expression in adherens
junction components may have a poorer long-term outcome
on therapy with a selective ER modulator and that such obser-
vations may ultimately extend to steroidal anti-oestrogens.
Such changes in expression might be inherent in a subpopu-
lation of breast cancer patients, or induced by long-term endo-
crine treatment, where prolonged exposure to tamoxifen can
promote growth factor pathway activation and the resultant
modulation of E-cadherin/catenin function [43]. In such cases,
adjuvant tamoxifen therapy may induce expression of pro-inva-
sive genes and promote an adverse cell phenotype given the
absence of cell-cell adhesion. We suggest this may lead to an
increased risk of aggressive behaviour of recurrences on ther-
apy and hence impact substantially on prognosis. Signifi-
cantly, our recent studies in an additional ER-positive, E-
cadherin-positive breast cancer cell model (T47D cells) also
demonstrate that similar pro-invasive effects can be elicited by
tamoxifen following suppression of E-cadherin; importantly,
this is also accompanied by an increase in Src activity [see
Additional data file 1] thus suggesting that these events are
not specific to MCF-7 cells, but may represent a generic effect
in such breast cancer subtypes.
Importantly, although it might be tempting to speculate that
suppression of E-cadherin in MCF-7 cells may represent a
model of lobular carcinoma, a subset of breast cancers char-
acterised by low/absent E-cadherin expression [44], this is
unlikely because lobular carcinomas are likely to have a multi-
tude of additional changes in gene expression and signalling
pathway activity separate from that of a loss in E-cadherin
expression. Indeed, a recent report by Rakha and colleagues
[45] shows that about 20% of invasive ductal carcinomas
have no E-cadherin but are still classed as ductal rather than
lobular. Moreover, a number of studies have shown that lobular
Figure 6
Fulvestrant enhances breast cancer cell invasion in absence of intercellular adhesion Fulvestrant enhances breast cancer cell invasion in absence of intercellular adhesion. (a) Fulvestrant also induces invasion in absence of inter-
cellular adhesions, which is accompanied by an (b) increase in Src kinase activity. (c) No effects are seen in MDA-MB-231 cell invasion following 
fulvestrant treatment.Breast Cancer Research    Vol 10 No 6    Borley et al.
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cancer is a distinct entity of breast cancer that differs from
ductal not only in histological and clinical features but also in
global transcription programmes [46] and genomic profiles
[47].
Lobular carcinomas are generally considered to have more
favourable pathological characteristics than ductal carcino-
mas, including being more likely to express hormone recep-
tors. Although in the early years after diagnosis the prognosis
for patients with lobular cancers who receive endocrine ther-
apy appears better than for those with ductal cancers, the
overall outcome for lobular cancers may be worse as these
show a persistent early relapse rate [45]. Indeed, a recent
paper by Pestalozzi and colleagues [48] reports that lobular
cancers, despite fairing slightly better than invasive ductal can-
cers initially, are significantly associated with a reduction in
disease-free survival when compared with invasive ductal car-
cinomas. Such data might suggest that anti-oestrogens may
have a beneficial effect on proliferative responses initially but
pro-invasive genes expressed over time may promote an inva-
sive phenotype and thus a poor prognosis in cancers lacking
E-cadherin. However, no data is currently available concerning
the anti-oestrogen-induced expression of pro-invasive genes
in lobular cancers. The future availability of in vitro cell models
of lobular cancer will allow the further examination of anti-oes-
trogen effects in cells representative of this breast cancer
subtype.
Whether tamoxifen-induced cell invasion is a direct result of E-
cadherin manipulation or arises from changes within other
junction proteins (eg, -catenin) whose function can be altered
after E-cadherin deregulation, or as a result of a loss of cell-cell
adhesion per se, is unknown at present. We are currently
examining a series of clinical breast cancers from the Adjuvant
Breast Cancer trial [49] to investigate if E-cadherin (and/or its
associated adherens-junction proteins) is a marker of earlier
relapse and poorer prognosis on tamoxifen therapy. We sug-
gest further similar studies, correlating E-cadherin expression
with outcome, be carried out within the large adjuvant aro-
matase inhibitor trials.
Conclusion
Taken together, our pre-clinical data generates the hypothesis
that in patients whose primary breast cancers show reduced
or aberrant E-cadherin expression, tamoxifen therapy may pro-
mote the development of an adverse cell phenotype that may
have an impact on disease relapse, its invasive behaviour and
hence patient survival. Although our observations may only
apply to a relatively small subset of patients, they may account
for some of the superiority seen with aromatase inhibitors in
the large adjuvant studies. If these findings are borne out, E-
cadherin expression could be used a biomarker to help guide
the choice of adjuvant endocrine therapy.
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